Ulcerative colitis (UC) is a chronic disorder that involves inflammation. This study was carried out to examine the anti-inflammatory effect of the methanol extract of Brideliaferrugineastem barkinAcetic acid-induced ulcerative colitis inmaleWistarrats. Twenty-four rats were randomly divided into 6 groups of 4 animals each, colitis was thereafter induced by intrarectal administration of4% (v/v)Aceticacidin all except group 1, which received distilled water. For post-colitis induction treatment group 2 received distilled water, groups 3, 4 and 5 were orally administeredthe extract at doses of 100mg/kg, 200mg/kg and 400mg/kg, respectively while group 6 received sulfasalazine 500mg/kg orally.Post colitis induction, treatment lasted for 7 days and at the end of the experiment, colon samples were collected for estimation of antioxidant, inflammatory and histological parameters. Molecular docking study was also carried out to gain more insights about the promising anti-inflammatory compounds earlier identified in the extract.Results revealed that the extract significantly (p<0.05) attenuated the increased MDA, nitrite,TNF-α and IL-6 levels. Activities of SOD, CAT, MPO and GSH levelswere also, significantly (p<0.05) increased. Furthermore, molecular docking study revealed that α-amyrin may have contributed significantly to the anti-inflammatory activity of the extract because of its remarkable binding affinity for IL-6, iNOS, IL1-β,TNF-α and COX-2 relative to prednisolone and celecoxib. This study suggests that the extract attenuated acetic acid-induced colitis via antioxidative and anti-inflammatory mechanisms. .
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.54548/njps.v38i1.12 | DOI Listing |
J Crohns Colitis
January 2025
Servei d'Aparell Digestiu, Hospital Universitari Germans Trias i Pujol (Badalona, Catalonia, Spain).
Background And Aims: Inflammatory bowel disease (IBD) develops in genetically susceptible individuals exposed to certain environmental factors, of which only a few have been established. We aimed to assess whether bariatric surgery (BS) and severe obesity are associated with an increased risk of developing IBD.
Methods: Adults diagnosed with obesity or severe obesity between 2005 and 2020 were identified from the Catalan Health Surveillance System; those diagnosed with IBD prior to the diagnosis of obesity or severe obesity were excluded.
Dig Dis Sci
January 2025
Department of Gastroenterology, Hepatology, and Nutrition, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH, 44195, USA.
Background: Ulcerative colitis patients who undergo ileal pouch-anal anastomosis (IPAA) without mucosectomy may develop inflammation of the rectal cuff (cuffitis). Treatment of cuffitis typically includes mesalamine suppositories or corticosteroids, but refractory cuffitis may necessitate advanced therapies or procedural interventions. This review aims to summarize the existing literature regarding treatments options for cuffitis.
View Article and Find Full Text PDFAliment Pharmacol Ther
January 2025
Division of Gastroenterology and Hepatology, Department of Medicine, McGill University Health Center, Montreal, Quebec, Canada.
Background: Novel colorectal cancer endoscopic surveillance techniques for inflammatory bowel disease (IBD) have recently been developed.
Aims: Compare the efficacy of currently available techniques for dysplasia detection in colonic IBD.
Methods: We conducted a systematic literature search from inception to March 2024 for randomized controlled trials (RCTs) or prospective cohort studies enrolling adults with IBD and having surveillance colonoscopy for dysplasia screening.
Rev Gastroenterol Peru
January 2025
Servicio de Gastroenterología, Hospital Clínico de la Universidad de Chile, Universidad de Chile, Santiago, Chile.
Introduction: Despite advancements in therapeutic strategies, corticosteroids continue to play a role in inducing remission in Inflammatory Bowel Disease (IBD). Unfortunately, these drugs are often misused.
Objectives: To assess the dose and duration of corticosteroid therapy,and the subsequent change in treatment among patients with IBD.
J Crohns Colitis
January 2025
Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, USA.
Background: Extraintestinal Manifestations (EIMs) of Inflammatory Bowel Disease (IBD) are frequently experienced by patients and may lead to severe symptoms and fatigue. However, the reporting patterns of these outcomes in IBD randomized controlled trials (RCTs) is not clear.
Methods: We searched placebo controlled phase 3 RCTs of advanced therapies in IBD and assessed the frequency and means of reporting EIM and fatigue data in these studies.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!